BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 15048066)

  • 21. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells.
    Afford SC; Ahmed-Choudhury J; Randhawa S; Russell C; Youster J; Crosby HA; Eliopoulos A; Hubscher SG; Young LS; Adams DH
    FASEB J; 2001 Nov; 15(13):2345-54. PubMed ID: 11689460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells.
    De Cecco L; Capaia M; Zupo S; Cutrona G; Matis S; Brizzolara A; Orengo AM; Croce M; Marchesi E; Ferrarini M; Canevari S; Ferrini S
    PLoS One; 2015; 10(8):e0134706. PubMed ID: 26305332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
    Kitada S; Zapata JM; Andreeff M; Reed JC
    Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
    Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.
    De Fanis U; Romano C; Dalla Mora L; Sellitto A; Guastafierro S; Tirelli A; Bresciano E; Giunta R; Lucivero G
    Oncol Rep; 2003; 10(3):653-8. PubMed ID: 12684639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis.
    Fulda S; Meyer E; Friesen C; Susin SA; Kroemer G; Debatin KM
    Oncogene; 2001 Mar; 20(9):1063-75. PubMed ID: 11314043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deregulated c-Myc prematurely recruits both Type I and II CD95/Fas apoptotic pathways associated with terminal myeloid differentiation.
    Amanullah A; Liebermann DA; Hoffman B
    Oncogene; 2002 Feb; 21(10):1600-10. PubMed ID: 11896589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.
    Assohou-Luty C; Gerspach J; Siegmund D; Müller N; Huard B; Tiegs G; Pfizenmaier K; Wajant H
    J Mol Med (Berl); 2006 Sep; 84(9):785-97. PubMed ID: 16924474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An apoptosis signaling pathway induced by the death domain of FADD selectively kills normal but not cancerous prostate epithelial cells.
    Morgan MJ; Thorburn J; Thomas L; Maxwell T; Brothman AR; Thorburn A
    Cell Death Differ; 2001 Jul; 8(7):696-705. PubMed ID: 11464214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inducible resistance to Fas-mediated apoptosis in B cells.
    Rothstein TL
    Cell Res; 2000 Dec; 10(4):245-66. PubMed ID: 11191348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma.
    Plander M; Ugocsai P; Seegers S; Orsó E; Reichle A; Schmitz G; Hofstädter F; Brockhoff G
    Ann Hematol; 2011 Dec; 90(12):1381-90. PubMed ID: 21465189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules.
    Park SM; Schickel R; Peter ME
    Curr Opin Cell Biol; 2005 Dec; 17(6):610-6. PubMed ID: 16226446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
    An S; Yap D; Knox KA
    Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential regulation of Fas-mediated apoptosis of rheumatoid synoviocytes by tumor necrosis factor alpha and basic fibroblast growth factor is associated with the expression of apoptosis-related molecules.
    Kobayashi T; Okamoto K; Kobata T; Hasunuma T; Kato T; Hamada H; Nishioka K
    Arthritis Rheum; 2000 May; 43(5):1106-14. PubMed ID: 10817565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis through CD95 (Fas/APO-1), but not a CD40/CD95 chimeric receptor, is inhibited by phorbol-12-myristate-13-acetate.
    Rudert F; Wang Y; Lindridge E; Watson J
    DNA Cell Biol; 1997 Feb; 16(2):197-205. PubMed ID: 9052740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
    Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation and analysis of components of CD95 (APO-1/Fas) death-inducing signaling complex.
    Scaffidi C; Krammer PH; Peter ME
    Methods; 1999 Apr; 17(4):287-91. PubMed ID: 10196099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.
    Dranitzki-Elhalel M; Huang JH; Sasson M; Rachmilewitz J; Parnas M; Tykocinski ML
    Int Immunol; 2007 Apr; 19(4):355-63. PubMed ID: 17314083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.